UBS AG Logo
Login | Preferences | Contact |engita
UBS Fund Gate - Luxembourg
   
Home
News
Products
Compare products
Virtual portfolios
E-mail subscription
General information
 
 
Search for products
Overview
Search by criteria
Product information
UBS products  ›  Product information
UBS (Lux) Equity Fund - Health Care (USD) P-acc
ISIN no.:  LU0085953304
PDF
PDF
PDF
Overview  
Category profile
UBS Sector Funds target investors who want to capture opportunities in specific global sectors. Our fund managers utilise UBS's extensive research and portfolio management expertise to identify opportunities arising from difference between the market price of a stock and its intrinsic value.

Fund description
Actively managed equity portfolio investing worldwide in companies from the healthcare sector.
Efficient means of exploiting the potential of companies operating in the healthcare sector.
Specialised sector analysts seek out the most attractive stocks in the healthcare sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.

Key benefits
Easy access to the global healthcare sector
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
UBS’s proprietary fundamental valuation approach allows consistent identification of the most attractive global health care companies
Investors benefit from a global investment platform of UBS Asset Management.

Risks
UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Product features
Product category
UBS Equity Funds
UBS Sector Funds
Product domicile
Luxembourg
Portfolio management
UBS Asset Management
Fund management
UBS Fund Management (Luxembourg) S.A.
Custodian bank
UBS Europe SE, Luxembourg Branch
Day of inception
May 27, 1998
Currency of account
USD
Close of financial year
November 30
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Management fee
1.63% p.a.
Total expense ratio (TER)
2.11% p.a.
Swing pricing
yes
Minimum investment
n.a.
Reference Index / Benchmark
MSCI World Health Care (r)

Current data
Net asset value
USD274.12
18/07/2018
High - last 12 months
USD278.40
26/01/2018
Low - last 12 months
USD245.36
23/03/2018
Assets of the unit class in mn
USD133.18
18/07/2018
Total product assets in mn
USD178.18
18/07/2018

Statistical data
 
2 years
5 years
 
Total risk reference index / benchmark
10.28%
11.23%
29/06/2018
Sharpe Ratio
0.44
0.77
29/06/2018
Risk Free Rate
1.17%
0.66%
29/06/2018

Symbols
ISIN no.
LU0085953304
Bloomberg Ticker
UBSEHLI LX
Reuters Id
UBSFUNDS10
Telekurs Id
EQHC

 
Performance chart (USD-based, as of July 18, 2018)
Indexed, Month-end values
Performance chart (USD-based, as of July 18, 2018)

Past performance is not a reliable indicator of future results.

Performance (in %, as of July 18, 2018)
in %
1
year
3
years
5
years
ø p.a.
5 years
USD
5.77
2.47
61.14
10.01
EUR
5.22
-4.47
81.20
12.62
The performance shown does not take account of any commissions, entry or exit charges.
These figures refer to the past. Past performance is not a reliable indicator of future results.
Peer group (as of June 30, 2018)
 
1
year
3
years
5
years
Fund (USD, in%)
1.59
3.12
62.79
Ø peer group (in %) 1)
6.87
8.20
62.45
Quartile ranking 2)
3
3
2
1)  Average performance Lipper Global Classification (LGC)
2)  Quartile 1,2,3,4; e.g.: 1= fund is part of the best 25% of all funds of the peer group
Peer group information. Peer group category used: LGC Equity Sector Healthcare, based on mutual funds in the "MSCI Europe Developed Markets Universe" ex institutional and insurance funds, ETF's and Pension Trusts. Source and calculation: Lipper, a Thomson Reuters Company

By investment domicile (in %, as of June 29, 2018)
Chart

By the 10 largest equity positions (in %, as of June 29, 2018)
UnitedHealth Group Inc
8.82
Johnson & Johnson
8.09
Sanofi
6.22
Abbott Laboratories
5.63
Allergan PLC
5.46
GlaxoSmithKline PLC
4.49
Novartis AG
4.47
Bio-Rad Laboratories Inc
4.29
Laboratory Corp of America Holdings
3.52
Eli Lilly & Co
3.34

By sector (in %, as of June 29, 2018)
Chart
Up to 31 January 2006, MSCI benchmark with gross dividends reinvested, from 1 February 2006 with net dividends reinvested.
Additional fees (e.g. entry or exit fees) may be charged by the Distributor. Please refer to your financial adviser for more details. For a definition of financial terms refer to the glossary available at www.ubs.com/glossary.
For marketing and information purposes by UBS. UBS funds under Luxembourg law. Prospectuses, simplified prospectuses or key investor information, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from Northern Trust Global Services Limited, Luxembourg Branch, 6, rue Lou Hemmer, L-1748 Senningerberg or from UBS Europe SE, Luxembourg Branch, P.O. Box 2, L-2010 Luxembourg. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. Before investing in a product please read the latest prospectus carefully and thoroughly. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS AG. Source for all data and charts (if not indicated otherwise): UBS Asset Management
Source for all data and charts (if not indicated otherwise): UBS Asset Management
No responsibility is taken for the correctness of the information provided above.

Important legal information - please read the disclaimer before proceeding.
Products and services in these web pages may not be available for residents of certain nations.
Please consult the sales restrictions relating to the service in question for further information.
© UBS 1998-2018. All rights reserved.
Privacy Policy